| Name | Title | Contact Details |
|---|
Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.
Oculus Innovative Sciences, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Wake Researchs network of high-quality research sites and millions of patients is built on decades of experience meeting the needs of sponsors & CROs.
On the Forefront of COVID-19 Recognized leader in the COVID-19 field by governmental and non-governmental organizations as the reference assay...
Kinect is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.